[Effect of sub-pressor doses of dopamine on renin secretion in the anesthetized dog]. 1981

C Posadas, and J L Boyer, and J Guzmán, and J Figueroa, and A Millán, and G Sánchez, and P A Serrano

The effects of dopamine, its precursor L-dopa, and the dopaminergic agonist bromocriptine (BEC), on plasma renin activity (PRA), in pentobarbital anesthetized male dogs were investigated. Infusion of dopamine at a dose which did not change blood pressure ( 4 ug/kg/min) had no effect on the secretion of renin, nor did it produce modifications in the PRA response to furosemide (10 mg i.v.). L-dopa, in single dose of 500 mg (p.o), significantly augmented PRA two hours after administration, and the renin values remained elevated throughout the observation period of 120 minutes. However, BEC (2.5 mg p.o.) produced no changes in PRA during this time period. We conclude that at the dose utilized, dopamine apparently has no influence on the secretion of renin, and does not modify the increase in PRA provoked by diuretic. It is possible that the L-dopa induced augmentation in PRA is due to stimulation of the juxtaglomerular cells, by the noradrenaline formed in peripheral tissues from administered L-dopa.

UI MeSH Term Description Entries
D007606 Juxtaglomerular Apparatus A complex of cells consisting of juxtaglomerular cells, extraglomerular mesangium lacis cells, the macula densa of the distal convoluted tubule, and granular epithelial peripolar cells. Juxtaglomerular cells are modified SMOOTH MUSCLE CELLS found in the walls of afferent glomerular arterioles and sometimes the efferent arterioles. Extraglomerular mesangium lacis cells are located in the angle between the afferent and efferent glomerular arterioles. Granular epithelial peripolar cells are located at the angle of reflection of the parietal to visceral angle of the renal corpuscle. Apparatus, Juxtaglomerular
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D010424 Pentobarbital A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236) Mebubarbital,Mebumal,Diabutal,Etaminal,Ethaminal,Nembutal,Pentobarbital Sodium,Pentobarbital, Monosodium Salt,Pentobarbitone,Sagatal,Monosodium Salt Pentobarbital
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine

Related Publications

C Posadas, and J L Boyer, and J Guzmán, and J Figueroa, and A Millán, and G Sánchez, and P A Serrano
August 1975, European journal of pharmacology,
C Posadas, and J L Boyer, and J Guzmán, and J Figueroa, and A Millán, and G Sánchez, and P A Serrano
September 1964, The American journal of physiology,
C Posadas, and J L Boyer, and J Guzmán, and J Figueroa, and A Millán, and G Sánchez, and P A Serrano
May 1972, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
C Posadas, and J L Boyer, and J Guzmán, and J Figueroa, and A Millán, and G Sánchez, and P A Serrano
November 1978, European journal of pharmacology,
C Posadas, and J L Boyer, and J Guzmán, and J Figueroa, and A Millán, and G Sánchez, and P A Serrano
February 1972, Biochemical pharmacology,
C Posadas, and J L Boyer, and J Guzmán, and J Figueroa, and A Millán, and G Sánchez, and P A Serrano
October 1968, Japanese circulation journal,
C Posadas, and J L Boyer, and J Guzmán, and J Figueroa, and A Millán, and G Sánchez, and P A Serrano
August 1987, Experientia,
C Posadas, and J L Boyer, and J Guzmán, and J Figueroa, and A Millán, and G Sánchez, and P A Serrano
December 1971, British journal of pharmacology,
C Posadas, and J L Boyer, and J Guzmán, and J Figueroa, and A Millán, and G Sánchez, and P A Serrano
August 1978, Il Farmaco; edizione scientifica,
C Posadas, and J L Boyer, and J Guzmán, and J Figueroa, and A Millán, and G Sánchez, and P A Serrano
January 1977, Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie,
Copied contents to your clipboard!